Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
주식 순위 #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
주가
$0.02765
마지막 동기화: 2024-12-23
시가총액
$69.04K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Histogen Inc. (HSTO)

카테고리

Histogen Inc. (HSTO)의 수익
Sep 2023 기준 수익 TTM: $-12.38M
Histogen Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-12.38M입니다. 2021년에 회사는 $-15.01M의 수익을 올렸으며 이는 2020년의 수익 $-18.82M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Histogen Inc.의 수익 기록 (2011 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-12.38M 16.35%
2022 $-10.64M -29.08%
2021 $-15.01M -20.24%
2020 $-18.82M 65.28%
2019 $-11.39M -36.79%
2018 $-18.01M 3.53%
2017 $-17.40M -41.49%
2016 $-29.73M 23.12%
2015 $-24.15M 8.19%
2014 $-22.32M 42.93%
2013 $-15.62M 78.48%
2012 $-8.75M -27.07%
2011 $-12.00M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -42,694.48%
US
$1.95B -15,851.37%
NL
- -
CH
- -
KR
$3.01B -24,370.97%
BE